Robb Gary Charles's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Mar 18, 2022
- Accession no.
- 0000899243-22-011614
- Filed
- Mar 18, 2022
- Trade date
- Mar 17-18, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $308.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Robb Gary CharlesCIK 0001529655 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2022 | Common Stock | SSaleDisposed | −7,512 | $24.68F2 | −$185,396.16 | 76,434 | Direct | |
| Mar 18, 2022 | Common Stock | SSaleDisposed | −4,988 | $24.67 | −$123,053.96 | 71,446 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $24.67 to $24.70. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.